

May 6, 2020



Codexis Achieves Technology Transfer Milestone with Global Pharmaceutical Leader

REDWOOD CITY, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces achievement of the Wave 2 milestone associated with the CodeEvolver[®] platform technology transfer and license agreement with Novartis Pharma AG (“Novartis”) that was [executed in May, 2019](#). Completion of Wave 2 deliverables confirms that Novartis is now equipped to begin to practice the CodeEvolver[®] platform technology at its designated site.

“It is terrific to see the continued progress establishing Novartis as our newest CodeEvolver[®] licensing partner,” stated John Nicols, Codexis President and CEO. “Our progress in the technology transfer reinforces the collaboration and innovation at the heart of Codexis values.”

About Codexis, Inc.

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver[®] protein engineering technology to develop proteins for a variety of applications, including enzymes as biotherapeutics, as biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals, industrial enzymes, and for use in molecular diagnostics. For its Biotherapeutics pipeline, Codexis’ technology enables improvements in protein efficacy, through enhancement of activity, affinity, stability, as well as uptake by target cells. For more information, see www.codexis.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; Codexis’ dependence on a limited number of products and customers; and potential adverse effects to Codexis’ business if its customers’ products are not received well in the markets. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2020, including under the caption “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

LHA Investor Relations
Jody Cain, 310-691-7100
jcain@lhai.com



Source: Codexis, Inc.